Management tracks: Melinta, Editas, Accelerate, Santhera

John Johnson has resigned as CEO of Melinta Therapeutics Inc. (NASDAQ:MLNT). He will stay with the antibiotics company during the search for his successor. David Gill, a board member, was named chairman, replacing Kevin Ferro, who also resigned.

Editas Medicine Inc. (NASDAQ:EDIT) has named Cindy Collins president and CEO on a permanent basis. She was serving as interim CEO of the CRISPR company. Prior to joining Editas, she was CEO of Human Longevity Inc. (San Diego, Calif.)...